ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain ...

Abbott’s Infinity Deep Brain Stimulation (DBS) system has received an expanded clearance from the FDA that now permits the targeted stimulation of a new area of the brain associated with Parkinson’s ...

Abbott Laboratories is launching a clinical trial applying its deep brain stimulation system to a tough-to-treat form of depression. The company called its "Transcend" study a pivotal trial for ...

The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this ...